Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Sue O'Dorisio
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01869725CT.gov Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Somatostatinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Edotreotide (this asset) | Sue O'Dorisio | P2 | CCC · 55 |
| Capecitabine | Vanderbilt-Ingram Cancer Center | P2 | BB |
| Everolimus | Emory University | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
| Gefitinib | National Cancer Institute (NCI) | P2 | B |
| Pazopanib | National Cancer Institute (NCI) | P2 | B |
| Regorafenib | University of Southern California | P2 | B |
| Romidepsin | National Cancer Institute (NCI) | P2 | CCC |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | National Cancer Institute (NCI) | P1 | CC |
+7 more in the Somatostatinoma cohort
Other indications for Edotreotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Neuroendocrine Neoplasm | — | P3 | B · 63 |
| Neuroblastoma | — | P2 | B · 60 |
| Carcinoid Tumor | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Edotreotide in Somatostatinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/edotreotide-somatostatinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →